Dr Reddy’s Laboratories Ltd has launched Bupropion Hydrochloride Extended-Release Tablets a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) tablets in the US market.
According to a release issued by the Hyderabad-based company here on Wednesday, the Wellbutrin XL brand and generic had US sales of approximately $754 million for the most recent twelve months ending in July 2017 according to IMS Health. Wellbutrin XL is a trademark of GlaxoSmithKline LLC.
Dr Reddy’s scrip lost 0.70 per cent and was trading at Rs 2,193.05 on the Bombay Stock Exchange on Wednesday
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.